Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fecal Immunochemical Test Effective for Annual Colon Cancer Screening

By LabMedica International staff writers
Posted on 10 Feb 2016
The fecal immunochemical test (FIT) is highly sensitive for detecting colorectal cancer, and adherence to annual follow-up screening among initial participants is high, making the noninvasive test feasible and effective for annual colorectal cancer screening programs. More...


Colorectal cancer (CRC) is the second leading cause of cancer death in the USA. Evidence shows that highly sensitive guaiac-based fecal occult blood tests (FOBT), which are recommended for annual screening of average risk patients between the ages of 50 and 75, can reduce morbidity and mortality from colorectal cancer. FIT has higher detection rates for CRC and advanced adenomas than FOBT, but little is known about how well FIT works over several rounds of annual screening.

Scientists working for Kaiser Permanente (Oakland, CA, USA) and their colleagues carried out a retrospective cohort study and collected data on 323,349 health plan members aged 50 to 70 years. The members were on their FIT mailing date in 2007 or 2008 and had completed the first round of FIT and were followed for up to four screening rounds. Screening participation included an FIT positivity, equal to or greater than 20 µg of hemoglobin/g, which has positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.

Of the patients invited for screening, 48.2% participated in round one. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of first round participants crossed over to endoscopy over four screening rounds and 7.0% were due to a positive FIT result. The FIT positivity rate of 5.0% and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in the first round.

Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within one year of testing, including 84.5% in round one and 73.4% to 78.0% in subsequent rounds. The authors concluded that annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening. The study was published on January 26, 2016, in the journal Annals of Internal Medicine.

Related Links:

Kaiser Permanente



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Collection and Transport System
PurSafe Plus®
Laboratory Software
ArtelWare
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.